secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001558370-22-013557
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix Q2 net loss narrows to $5.3M; PRX-102 Phase III CSR complete
---------------------------------------------------------------------

- Total revenues $8.8M ($3.4M product sales +$5.4M license/R&D), up 38% YoY.
- Net loss $5.3M ($0.11/share) vs. $11.2M ($0.25/share) in Q2 2021.
- Cash and equivalents $28.6M at June 30, 2022.
- Phase III BALANCE trial CSR confirms positive topline results for PRX-102 in Fabry disease.
- Appointed Shmuel Ben Zvi, Ph.D. to Board as Audit Committee Chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022013557/0001558370-22-013557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837022013557/plx-20220815x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-013557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer